Skip to Content
Merck
  • Effect of iron fortification on malaria incidence in infants and young children in Ghana: a randomized trial.

Effect of iron fortification on malaria incidence in infants and young children in Ghana: a randomized trial.

JAMA (2013-09-05)
Stanley Zlotkin, Samuel Newton, Ashley M Aimone, Irene Azindow, Seeba Amenga-Etego, Kofi Tchum, Emmanuel Mahama, Kevin E Thorpe, Seth Owusu-Agyei
ABSTRACT

In sub-Saharan Africa, malaria is a leading cause of childhood morbidity and iron deficiency is among the most prevalent nutritional deficiencies. In 2006, the World Health Organization and the United Nations Children's Fund released a joint statement that recommended limiting use of iron supplements (tablets or liquids) among children in malaria-endemic areas because of concern about increased malaria risk. As a result, anemia control programs were either not initiated or stopped in these areas. To determine the effect of providing a micronutrient powder (MNP) with or without iron on the incidence of malaria among children living in a high malaria-burden area. Double-blind, cluster randomized trial of children aged 6 to 35 months (n = 1958 living in 1552 clusters) conducted over 6 months in 2010 in a rural community setting in central Ghana, West Africa. A cluster was defined as a compound including 1 or more households. Children were excluded if iron supplement use occurred within the past 6 months, they had severe anemia (hemoglobin level <7 g/dL), or severe wasting (weight-for-length z score <-3). Children were randomized by cluster to receive a MNP with iron (iron group; 12.5 mg/d of iron) or without iron (no iron group). The MNP with and without iron were added to semiliquid home-prepared foods daily for 5 months followed by 1-month of further monitoring. Insecticide-treated bed nets were provided at enrollment, as well as malaria treatment when indicated. Malaria episodes in the iron group compared with the no iron group during the 5-month intervention period. In intention-to-treat analyses, malaria incidence overall was significantly lower in the iron group compared with the no iron group (76.1 and 86.1 episodes/100 child-years, respectively; risk ratio (RR), 0.87 [95% CI, 0.79-0.97]), and during the intervention period (79.4 and 90.7 episodes/100 child-years, respectively; RR, 0.87 [95% CI, 0.78-0.96]). In secondary analyses, these differences were no longer statistically significant after adjusting for baseline iron deficiency and anemia status overall (adjusted RR, 0.87; 95% CI, 0.75-1.01) and during the intervention period (adjusted RR, 0.86; 95% CI, 0.74-1.00). In a malaria-endemic setting in which insecticide-treated bed nets were provided and appropriate malaria treatment was available, daily use of a MNP with iron did not result in an increased incidence of malaria among young children. clinicaltrials.gov Identifier: NCT01001871.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Iron, puriss. p.a., carbonyl-Iron powder, low in magnesium and manganese compounds, ≥99.5% (RT)
Iron, IRMM®, certified reference material, 0.5 mm wire
Sigma-Aldrich
Iron, chips, 99.98% trace metals basis
Sigma-Aldrich
Iron, foil, thickness 0.1 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Iron, powder, −325 mesh, 97%
Sigma-Aldrich
Iron, wire, diam. 1.0 mm, ≥99.9% trace metals basis
Sigma-Aldrich
Iron, granular, 10-40 mesh, >99.99% trace metals basis
Sigma-Aldrich
Iron, foil, thickness 0.25 mm, ≥99.99% trace metals basis
Sigma-Aldrich
Iron, ≥99%, reduced, powder (fine)
Sigma-Aldrich
Carbonyl iron, ≥97% Fe basis